Mustafa Ozguroglu
0000-0002-8417-8628
Istanbul University
315 papers found
Refreshing results…
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.
PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.
Pd10-11 Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in Titan: Prognostic Importance of Prostate-Specific Antigen Responses
Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab +/- Tremelimumab plus Chemotherapy in ES-SCLC
Central, Prospective Detection of Homologous Recombination Repair (HRR) Gene Alteration in Tumor Tissue From > 4000 Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Screened for The Profound Study
Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab$±$Tremelimumab+ Chemotherapy in ES-SCLC
Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in Titan: Prognostic Importance of Prostate-Specific Antigen Responses
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110
Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Three-year overall survival update from the PACIFIC trial
Missing publications? Search for publications with a matching author name.